| Preclinical platform for long-term evaluation of immuno-oncology drugs using hCD34+ humanized mouse model N Park, K Pandey, SK Chang, AY Kwon, YB Cho, J Hur, NB Katwal, ... Journal for Immunotherapy of Cancer 8 (2), 2020 | 22 | 2020 |
| Synergism of AZD6738, an ATR inhibitor, in combination with belotecan, a camptothecin analogue, in chemotherapy-resistant ovarian cancer J Hur, M Ghosh, TH Kim, N Park, K Pandey, YB Cho, SD Hong, ... International Journal of Molecular Sciences 22 (3), 1223, 2021 | 21 | 2021 |
| Deregulated immune pathway associated with palbociclib resistance in preclinical breast cancer models: Integrative genomics and transcriptomics K Pandey, E Lee, N Park, J Hur, YB Cho, NB Katuwal, SK Kim, SA Lee, ... Genes 12 (2), 159, 2021 | 16 | 2021 |
| Combination of abemaciclib following Eribulin overcomes palbociclib-resistant breast cancer by inhibiting the G2/M cell cycle phase K Pandey, NB Katuwal, N Park, J Hur, YB Cho, SK Kim, SA Lee, I Kim, ... Cancers 14 (1), 210, 2022 | 7 | 2022 |
| Combined PI3K inhibitor and eribulin enhances anti-tumor activity in preclinical models of paclitaxel-resistant, PIK3CA-mutated endometrial cancer YG Jeong, NB Katuwal, MS Kang, M Ghosh, SD Hong, SM Park, SG Kim, ... Cancers 15 (19), 4887, 2023 | 2 | 2023 |
| PSPC1 Inhibition Synergizes with Poly (ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/Ovarian Cancer M Ghosh, MS Kang, NB Katuwal, SD Hong, YG Jeong, SM Park, SG Kim, ... International Journal of Molecular Sciences 24 (23), 17086, 2023 | 1 | 2023 |
| Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer NB Katuwal, MS Kang, M Ghosh, SD Hong, YG Jeong, SM Park, SG Kim, ... Journal of Experimental & Clinical Cancer Research 42 (1), 325, 2023 | 1 | 2023 |
| Abstract P2-26-09: Synergistic activity of PI3K inhibitor in combination with AZD6738, ATR inhibitor in breast cancer preclinical model via DNA damage response pathway YW Moon, M Gosh, N Park, K Pandey, NB Katwal, SD Hong Cancer Research 83 (5_Supplement), P2-26-09-P2-26-09, 2023 | 1 | 2023 |
| Preclinical Platform Using a Triple-negative Breast Cancer Syngeneic Murine Model to Evaluate Immune Checkpoint Inhibitors NB Katuwal, N Park, K Pandey, MS Kang, SD Hong, M Ghosh, SG Kim, ... Anticancer Research 43 (1), 85-95, 2023 | 1 | 2023 |
| JPI-547, a novel dual inhibitor of PARP 1/2 and tankyrase 1/2 overcomes olaparib resistance in BRCA 1/2 mutant ovary and breast cancer preclinical model MS Kang, N Katuwal, M Ghosh, Y Jeong, S deok Hong, SM Park, J Kim, ... Cancer Research 83 (7_Supplement), 4485-4485, 2023 | | 2023 |
| 885 Enhancing immune checkpoint inhibitor efficacy with anti-angiogenics in ovarian cancer S Gitto, S Medvedev, V Pandey, D Omran, M Anderson, L Schwartz, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
